FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
|Videos|October 22, 2019
A 59-Year-Old Man With Relapsed Follicular Lymphoma
A 59-Year-Old Man With Relapsed Follicular Lymphoma
Advertisement
Case: A 59-Year-Old Man With Symptomatic Follicular Lymphoma
A 59-year-old man presented to his physician with a 10-lb weight loss and chronic night sweats for the past couple of months. He complained of intermittent fatigue but is able to maintain his current exercise regimen.
H & P
- PE: enlarged bilateral axillary lymph nodes; enlarged spleen, palpable
- CBC: WBC, 12 X 104/L; platelets,103 X 109/L; Hgb, 9.2 g/dL
- LDH: 400 U/L
Biopsy
- Excisional biopsy showed grade 2 follicular lymphoma; CD20+, CD10+
- Bone marrow biopsy; 60% involved
Imaging
- PET/CT showed widespread lymphadenopathy and a large splenic mass measuring 10 cm
- Diagnosis: Stage IV follicular lymphoma
Teatment
- Started on R-CHOP; tolerated induction well
- Post-therapy PET showed partial remission
- Followed by Rituximab maintenance until evidence of disease progression
Follow-up
- Core needle biopsy; performed confirmed persistent follicular lymphoma; no transformation
- PET at 12 months showed increased size of splenic mass
- ECOG, 0
- Patient started on obinutuzumab + bendamustine
Advertisement
Related to this article
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
5